$Amphastar Pharmaceuticals (AMPH.US)$Revenue has been growin...
$Amphastar Pharmaceuticals (AMPH.US)$Revenue has continued to grow over the past 5 years, with a growth of 14% in 2022. Operating profit quickly increased to 0.11 billion yuan in 2020 after a loss, and increased by 53.8% in 2022. Net income grew by 44.4% to reach 0.091 billion yuan in 2022.
In Q1 2023, revenue increased by 16.3%, operating profit increased by 54.7%, and net income increased by 7.3%, mainly due to other net income of 9.07 million yuan in the same period last year.
The asset-liability ratio has remained relatively stable over the past 5 years, fluctuating around 30%. The proportion and growth rate of accounts receivable and inventory are relatively normal.
Long-term borrowings are 0.073 billion yuan, net assets are 0.55 billion yuan, the leverage ratio is very low, and there are 0.198 billion yuan of treasury stocks.
In the past 3 years, the operating net cash flow has started to significantly exceed the net investment, generating shareholder surplus.
Currently, the PE ratio is 25.4, the TTM PE ratio is 24.9, and there is a certain discount on the growth rate ratio, but high growth is inherently unsustainable, so it should be chosen cautiously (⭐️)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
